Understanding patients' perspective of statin therapy: Can we design a better approach to the management of dyslipidaemia? A literature review

Singapore Medical Journal

Volumn 55, Issue 8, 2014, Pages 416-421

  Chee, Ying Jie ^a   Chan, Hian Hui Vincent ^b   Tan, Ngiap Chuan ^b,c  

^a TAN TOCK SENG HOSPITAL   (Singapore)

^b SingHealth Polyclinics Pasir Ris   (Singapore)

^c DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

Adherence; Dyslipidaemia; Patient; Perceptions; Statin

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN;

ACUTE HEART INFARCTION; ARTICLE; DISEASE SEVERITY; DOCTOR PATIENT RELATION; DRUG COST; DYSLIPIDEMIA; HEALTH BELIEF MODEL; HUMAN; HYPERCHOLESTEROLEMIA; INFORMATION RETRIEVAL; INTERPERSONAL COMMUNICATION; MEDICAL DECISION MAKING; MEDICATION COMPLIANCE; META ANALYSIS (TOPIC); MYALGIA; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT SATISFACTION; PERCEPTION; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHABDOMYOLYSIS; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; ATTITUDE TO HEALTH; CARDIOVASCULAR DISEASES; DIET; DYSLIPIDEMIAS; HEALTH EDUCATION; MYOCARDIAL INFARCTION; PATIENT ATTITUDE; RISK FACTOR; SINGAPORE; STROKE;

ATTITUDE TO HEALTH; CARDIOVASCULAR DISEASES; DIET; DYSLIPIDEMIAS; HEALTH EDUCATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MEDICATION ADHERENCE; MYOCARDIAL INFARCTION; PATIENT ACCEPTANCE OF HEALTH CARE; PHYSICIAN-PATIENT RELATIONS; RISK FACTORS; SINGAPORE; STROKE;

EID: 84907357546     PISSN: 00375675     EISSN: None     Source Type: Journal    
DOI: 10.11622/smedj.2014099     Document Type: Article

References (51)

1. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267-78.
2. Cholesterol Treatment Trialists' (CTT) Collaborators, Mihaylova B, Emberson J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380:581-90.
3. Bates TR, Connaughton VM, Watts GF. Non-adherence to statin therapy: a major challenge for preventive cardiology. Expert Opin Pharmacother 2009; 10:2973-85.
4. Ho KT, Chin KW, Ng KS, et al. The A-SACT (Achievement in Singapore of Cholesterol Targets) study in patients with coronary heart disease. Am J Cardiovasc Drugs 2006; 6:383-91.
5. Ansell BJ. Not getting to goal: the clinical costs of noncompliance. J Manag Care Pharm 2008; 14:9-15.
6. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005; 43:521-30.
7. Chaudhry HJ, McDermott B. Recognizing and improving patient nonadherence to statin therapy. Curr Atheroscler Rep 2008; 10:19-24.
8. Ford I, Murray H, Packard CJ, et al. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 2007; 357:1477-86.
9. Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002; 288:455-61.
10. Rosenstock IM, Strecher VJ, Becker MH. Social learning theory and the Health Belief Model. Health Educ Q 1988; 15:175-83.
11. Wong MC, Jiang JY, Griffiths SM. Adherence to lipid-lowering agents among 11,042 patients in clinical practice. Int J Clin Pract 2011; 65:741-8.
12. Mann DM, Woodward M, Muntner P, Falzon L, Kronish I. Predictors of nonadherence to statins: a systematic review and meta-analysis. Ann Pharmacother 2010; 44:1410-21.
13. Chan DC, Shrank WH, Cutler D, et al. Patient, physician, and payment predictors of statin adherence. Med Care 2010; 48:196-202.
14. Durack-Bown I, Giral P, d'Ivernois JF, et al. Patients' and physicians' perceptions and experience of hypercholesterolaemia: a qualitative study. Br J Gen Pract 2003; 53:851-7.
15. Goldman RE, Parker DR, Eaton CB, et al. Patients' perceptions of cholesterol, cardiovascular disease risk, and risk communication strategies. Ann Fam Med 2006; 4:205-12.
16. Fung V, Sinclair F, Wang H, et al. Patients' perspectives on nonadherence to statin therapy: a focus-group study. Perm J 2010; 14:4-10.
17. McHorney CA. The Adherence Estimator: a brief, proximal screener for patient propensity to adhere to prescription medications for chronic disease. Curr Med Res Opin 2009; 25:215-38.
18. Mann DM, Allegrante JP, Natarajan S, Halm EA, Charlson M. Predictors of adherence to statins for primary prevention. Cardiovasc Drugs Ther 2007; 21:311-6.
19. McClendon D. Perceived Susceptibility of Cardiovascular Disease as a Moderator of Relationships between Perceived Severity and Cardiovascular Health Promoting Behaviors among Female Registered Nurses (dissertation). Atlanta, GA: Georgia State University, 2011.
20. DiMatteo MR, Haskard KB, Williams SL. Health beliefs, disease severity, and patient adherence: a meta-analysis. Med Care 2007; 45:521-8.
21. Yan J, You LM, He JG, et al. Illness perception among Chinese patients with acute myocardial infarction. Patient Educ Couns 2011; 85:398-405.
22. Choudhry NK, Setoguchi S, Levin R, Winkelmayer WC, Shrank WH. Trends in adherence to secondary prevention medications in elderly post-myocardial infarction patients. Pharmacoepidemiol Drug Saf 2008; 17:1189-96.
23. Shah ND, Dunlay SM, Ting HH, et al. Long-term medication adherence after myocardial infarction: experience of a community. Am J Med 2009; 122:961.e7-13.
24. Colivicchi F, Bassi A, Santini M, Caltagirone C. Discontinuation of statin therapy and clinical outcome after ischemic stroke. Stroke 2007; 38:2652-7.
25. Gialamas A, Aylward P, Vanlint S, Stocks NP. Cholesterol lowering medication atients' knowledge, attitudes and experiences. Aust Fam Physician 2011; 40:519-22.
26. Tarn DM, Paterniti DA, Kravitz RL, et al. How much time does it take to prescribe a new medication? Patient Educ Couns 2008; 72:311-9.
27. Lytsy P, Westerling R. Patient expectations on lipid-lowering drugs. Patient Educ Couns 2007; 67:143-50.
28. McKenney JM, Davidson MH, Jacobson TA, Guyton JR; National Lipid Association Statin Safety Assessment Task Force. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol 2006; 97:89C-94C.
29. Ucar M, Mjörndal T, Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf 2000; 22:441-57.
30. Chapman MJ, Carrie A. Mechanisms of statin-induced myopathy: a role for the ubiquitin-proteasome pathway? Arterioscler Thromb Vasc Biol 2005; 25:2441-4.
31. Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study. Cardiovasc Drugs Ther 2005; 19:403-14.
32. Yilmaz MB, Pinar M, Naharci I, et al. Being well-informed about statin is associated with continuous adherence and reaching targets. Cardiovasc Drugs Ther 2005; 19:437-40.
33. Yilmaz MB, Biyikoglu SF, Guray Y, et al. Level of awareness of on-treatment patients about prescribed statins. Cardiovasc Drugs Ther 2004; 18:399-404.
34. National Heart, Lung, and Blood Institute. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III); 2001. NIH Publication No. 01-3670.
35. Varady KA, Jones PJ. Combination diet and exercise interventions for the treatment of dyslipidemia: an effective preliminary strategy to lower cholesterol levels? J Nutr 2005; 135:1829-35.
36. Ramsay LE, Yeo WW, Jackson PR. Dietary reduction of serum cholesterol concentration: time to think again. BMJ 1991; 303:953-7.
37. Jenkins DJ, Kendall CW, Marchie A, et al. Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA 2003; 290:502-10.
38. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA 2007; 298:61-9.
39. Doshi JA, Zhu J, Lee BY, Kimmel SE, Volpp KG. Impact of a prescription copayment increase on lipid-lowering medication adherence in veterans. Circulation 2009; 119:390-7.
40. Kripalani S, Yao X, Haynes RB. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med 2007; 167:540-50.
41. Choudhry NK, Winkelmayer WC. Medication adherence after myocardial infarction: a long way left to go. J Gen Intern Med 2008; 23:216-8.
42. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation 2009; 119:3028-35.
43. Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA 2006; 296:2563-71.
44. Weinman J, Petrie KJ, Moss-Morris R, Horne R. The illness perception questionnaire: a new method for assessing the cognitive representation of illness. Psychol Health 1996; 11:114-29.
45. Scharloo M, Kaptein AA, Weinman JA, et al. Predicting functional status in patients with rheumatoid arthritis. J Rheumatol 1999; 26:1686-93.
46. Scharloo M, Kaptein AA, Weinman J, et al. Patients' illness perceptions and coping as predictors of functional status in psoriasis: a 1-year follow-up. Br J Dermatol 2000; 142:899-907.
47. Scharloo M, Kaptein AA, Weinman JA, Willems LN, Rooijmans HG. Physical and psychological correlates of functioning in patients with chronic obstructive pulmonary disease. J Asthma 2000; 37:17-29.
48. Griva K, Myers LB, Newman S. Illness perceptions and self efficacy beliefs in adolescents and young adults with insulin dependent diabetes mellitus. Psychol Health 2000; 15:733-50.
49. Petrie KJ, Weinman J, Sharpe N, Buckley J. Role of patients' view of their illness in predicting return to work and functioning after myocardial infarction: longitudinal study. BMJ 1996; 312:1191-4.
50. Zolnierek KB, Dimatteo MR. Physician communication and patient adherence to treatment: a meta-analysis. Med Care 2009; 47:826-34.
51. Casebeer L, Huber C, Bennett N, et al. Improving the physician-patient cardiovascular risk dialogue to improve statin adherence. BMC Fam Pract 2009; 10:48.